The FDA said last week that it has reviewed more than 230 clinical trials of potential COVID-19 treatments so far through its Coronavirus Treatment Acceleration Program (CTAP).

More than 180 of the trials are in late-stage testing for safety and efficacy, while more than 40 are in early-stage testing for safety and dosing, the agency said.

More than 510 drug development programs for COVID-19 are currently in the planning stages.

“While we have shortened our timelines, our regulatory review and decision-making processes have not changed,” said FDA Commissioner Stephen Hahn in a joint statement with Patrizia Cavazzoni, acting director of the Center for Drug Evaluation and Research, and Peter Marks, director of the Center for Biologics Evaluation and Research.

The FDA launched CTAP in late March as an effort to accelerate COVID-19 therapies. The program is not involved in reviewing vaccines.